Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease.
Eva Cabrera CesarLidia Lopez-LopezEstrella LaraM Victoria Hidalgo-San JuanConcepcion Parrado RomeroJose Luis Royo Sánchez PalenciaElisa Martín-MontañezMaría Inmaculada García-FernándezPublished in: Journal of clinical medicine (2021)
In summary, our results provide support for the potential value of serum AGE, AOPP and MMP7 concentrations as diagnostic biomarkers in IPF and CTD-ILD to differentiate between ILD patients and healthy controls. Furthermore, this study provides evidence, for the first time, for the possible use of AGE as a differential diagnostic biomarker to distinguish between IPF and CTD-ILD. The value of these biomarkers as additional tools in a multidisciplinary approach to IPF and CTD-ILD diagnosis needs to be considered and further explored. Multicentre studies are necessary to understand the role of AGE in differential diagnosis.
Keyphrases
- interstitial lung disease
- idiopathic pulmonary fibrosis
- end stage renal disease
- systemic sclerosis
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- patient reported outcomes
- peritoneal dialysis
- rheumatoid arthritis
- study protocol
- climate change
- human health
- double blind